Orforglipron
Foundayo (orforglipron) is Eli Lilly's oral small-molecule GLP-1 receptor agonist. Phase 3 trials show up to 11.2% weight loss via daily pill — no injections required. Regulatory submissions expected 2026.
What is Orforglipron?
Orforglipron, branded as Foundayo by Eli Lilly, is an oral, once-daily, small-molecule GLP-1 receptor agonist. Unlike injectable GLP-1 agonists (semaglutide, tirzepatide) and even oral semaglutide (which requires SNAC absorption enhancer technology and strict fasting), orforglipron is a non-peptide small molecule that can be taken as a simple daily pill without food restrictions. It is technically not a peptide — it's a small molecule that mimics GLP-1 signaling — but it targets the same receptor and belongs to the same therapeutic class as semaglutide and tirzepatide. With 79 PubMed publications and multiple successful Phase 3 trials published in the New England Journal of Medicine, it is one of the most advanced oral obesity treatments in development. Eli Lilly is pursuing global regulatory submissions for Foundayo in 2026.
What Orforglipron Is Investigated For
Orforglipron (Foundayo) is Eli Lilly's investigational oral small-molecule GLP-1 receptor agonist positioned for chronic weight management, type 2 diabetes, weight maintenance after injectable GLP-1 therapy, and broader cardiometabolic risk reduction. The strongest evidence is in the obesity and T2D indications, with multiple Phase 3 trials published in the New England Journal of Medicine — ATTAIN-1 produced 11.2% weight loss at 36 mg over 72 weeks in 3,127 patients, ATTAIN-2 added efficacy in patients with T2D, and ACHIEVE-1 demonstrated glycemic benefit in early T2D. The honest framing on the evidence is that orforglipron is clinically meaningful but produces somewhat less peak weight loss than injectable semaglutide (~14%) and substantially less than tirzepatide (~20%) — its differentiator is convenience (daily pill, no fasting required, no injection), not superior efficacy. As of April 2026 it is investigational with 2026 global regulatory submissions planned; dedicated cardiovascular outcomes data is not yet available, long-term safety beyond 72 weeks is not established, and legitimate access is limited to clinical trials.
History & Discovery
Orforglipron (Lilly internal designation LY3502970) originated from Chugai Pharmaceutical's small-molecule GLP-1 receptor agonist program and was licensed by Eli Lilly in 2018. Its development is a notable chapter in GLP-1 history because it represents a deliberate attempt to achieve GLP-1 receptor agonism through a non-peptide small-molecule structure — sidestepping the oral bioavailability problem that historically made GLP-1 agonists injection-only, and doing so without the absorption-enhancer workarounds (SNAC technology) required for oral semaglutide. Phase 1 dose-escalation and safety studies were published in 2023. Phase 2 data in obesity and type 2 diabetes, also published in 2023 in the New England Journal of Medicine, established clinically meaningful weight loss and HbA1c reduction and supported advancement to large Phase 3 programs. Between 2024 and early 2026, Lilly reported results across the ACHIEVE series (type 2 diabetes) and ATTAIN series (obesity). ACHIEVE-1 reported positive topline efficacy in early type 2 diabetes in 2025. ATTAIN-1 demonstrated up to 11.2% mean weight loss at 36 mg over 72 weeks in a 3,127-participant obesity cohort. ATTAIN-2 evaluated obesity in people with type 2 diabetes. ATTAIN-MAINTAIN tested whether patients switching from injectable GLP-1s could maintain weight loss on oral orforglipron. Lilly announced plans for global regulatory submissions in 2026 under the brand name Foundayo. As of April 2026, orforglipron has not yet received FDA approval; its regulatory status is pending submissions and review.
How It Works
Foundayo (orforglipron) is a pill that mimics the GLP-1 hormone — the same target as Ozempic and Mounjaro. It tells your brain you're full, slows stomach emptying, and helps your body manage blood sugar. The breakthrough is that it's a small molecule rather than a peptide, so it survives digestion and can be taken as a simple daily pill.
Orforglipron is a non-peptide, small-molecule agonist of the GLP-1 receptor. Unlike peptide-based GLP-1 agonists that require injection or specialized oral delivery technology (SNAC for oral semaglutide), orforglipron's small-molecule structure confers oral bioavailability without absorption enhancers. It activates the GLP-1 receptor on pancreatic beta cells (enhancing glucose-dependent insulin secretion), hypothalamic appetite centers (reducing food intake), and gastric smooth muscle (slowing gastric emptying). Phase 3 data from ATTAIN-1 (3,127 participants, 72 weeks) demonstrated dose-dependent weight loss: -7.5% (6 mg), -8.4% (12 mg), and -11.2% (36 mg) vs -2.1% placebo. At 36 mg, 54.6% achieved at least 10% weight loss and 18.4% achieved at least 20%. Secondary improvements included waist circumference, systolic blood pressure, triglycerides, and non-HDL cholesterol. The ATTAIN-MAINTAIN trial demonstrated successful weight maintenance when patients switched from injectable GLP-1s to oral orforglipron.
Evidence Snapshot
Human Clinical Evidence
Strong. Multiple Phase 3 RCTs published in the New England Journal of Medicine. ATTAIN-1 (3,127 patients, obesity): 11.2% weight loss at 36 mg over 72 weeks. ATTAIN-2 (obesity + T2D): 10.5% weight loss at 36 mg with significant HbA1c reductions. ATTAIN-MAINTAIN: successful weight maintenance after switching from injectable GLP-1s. ACHIEVE-1: efficacy in early type 2 diabetes. Phase 1/2 dose-finding studies also published.
Animal / Preclinical
Not the primary evidence base — preclinical data supported advancement to human trials but clinical data now dominates.
Mechanistic Rationale
Strong. GLP-1 receptor agonism is one of the best-validated mechanisms in metabolic medicine, proven by semaglutide, tirzepatide, and liraglutide. Orforglipron achieves the same receptor activation through a novel small-molecule approach rather than peptide structure.
Research Gaps & Open Questions
What the current literature has not yet settled about Orforglipron:
- 01Cardiovascular outcomes — a dedicated cardiovascular outcomes trial (CVOT) equivalent to semaglutide's SELECT or tirzepatide's SURMOUNT-CVD has not been completed for orforglipron. CVOT data is typically required for GLP-1 labels extending beyond glycemic control, and orforglipron's positioning on cardiovascular risk reduction will depend on forthcoming trial readouts.
- 02Long-term safety beyond the 72-week Phase 3 window — chronic use data beyond trial duration does not yet exist, and GLP-1 agonists are chronic therapies for obesity and T2D.
- 03Head-to-head versus injectable GLP-1 and GLP-1/GIP agonists — direct comparative efficacy versus semaglutide 2.4 mg and tirzepatide is not established in randomized comparisons; existing comparisons are cross-trial.
- 04Pediatric and adolescent efficacy and safety — not yet studied.
- 05Effect on longer-term metabolic health markers (lean mass preservation, bone density, non-alcoholic fatty liver disease endpoints) — these are active questions across the GLP-1 class and not yet fully resolved for orforglipron.
- 06Real-world adherence and discontinuation dynamics — trial-setting adherence typically exceeds real-world adherence, and how orforglipron's oral-without-food-restrictions profile translates to real-world persistence is not yet known.
Forms & Administration
Orforglipron is taken as a once-daily oral tablet. Phase 3 trials tested 6 mg, 12 mg, and 36 mg doses with dose escalation over the first weeks of treatment. It does not require fasting or special administration conditions. It is currently only available through clinical trials and is not yet commercially available.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Phase 3 trials tested three maintenance doses: 6 mg, 12 mg, and 36 mg once daily, with weight-loss efficacy increasing with dose (approximately 7.5%, 8.4%, and 11.2% at 72 weeks in ATTAIN-1). Dose escalation over the first several weeks of treatment was used to improve GI tolerability. Final labeled doses, if and when orforglipron is approved, are expected to mirror the trial dose schedule, though specific label language will depend on FDA review.
Frequency
Once daily oral dosing. Unlike oral semaglutide (Rybelsus), orforglipron does not require fasting, a specific water volume, or a post-dose waiting period before eating — a consequence of its non-peptide small-molecule structure, which does not require SNAC-based absorption enhancement and is not subject to proteolytic degradation in the stomach in the same way peptide GLP-1 agonists are. This is a meaningful quality-of-life and adherence advantage relative to oral semaglutide.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
GLP-1 receptor agonists for obesity and type 2 diabetes are chronic, not cycled. Weight regain after discontinuation is well-documented across the GLP-1 class (STEP-4, SURMOUNT-4, and similar trials for semaglutide and tirzepatide), and ATTAIN-MAINTAIN was designed in part to address the question of long-term maintenance on oral orforglipron. 'Cycling' orforglipron is not a clinically supported pattern and would be expected to result in weight regain.
Protocol Notes
Orforglipron is technically not a peptide — it is a small-molecule non-peptide GLP-1 receptor agonist, and the site includes it in peptide discussions because it is commonly grouped with the GLP-1 class in patient and clinician conversations. The small-molecule structure is the reason for its differentiated oral profile: no injection, no fasting window, no specialized formulation technology. Dose escalation during initiation is the primary practical consideration, because GI adverse events (nausea, constipation, diarrhea, vomiting) cluster during titration. The Phase 3 trials used stepped titration over weeks to months; any eventual product label would be expected to follow a similar pattern. Because orforglipron is investigational as of April 2026 pending regulatory decisions, legitimate access is through clinical trials rather than a pharmacy prescription. Compounded orforglipron is not a legitimate access pathway: small-molecule non-peptide drugs are not within the scope of 503A peptide compounding, and any product marketed as 'compounded orforglipron' should be treated with significant skepticism.
These numbers reflect Phase 3 trial doses, not prescribing information. Orforglipron is not FDA-approved as of April 2026; regulatory review of Lilly's submissions is pending. Any use outside a clinical trial should be treated as off-protocol until approval is finalized.
Timeline of Effects
Onset
GLP-1-mediated appetite and satiety effects typically emerge within the first 1–2 weeks of dosing and track closely with dose escalation. Weight loss becomes measurable within the first month and accelerates over subsequent months. HbA1c reductions in type 2 diabetes cohorts were measurable by week 12 and continued through week 40 in Phase 3 data.
Peak Effect
In ATTAIN-1, mean weight loss continued to accrue through the full 72-week study duration at the 36 mg dose, with the weight-loss curve beginning to flatten but not fully plateau by the end of the trial. This pattern is consistent with injectable GLP-1 and GIP-GLP-1 agents, where maximum weight loss is typically observed somewhere between 52 and 104 weeks depending on agent and population.
After Discontinuation
Weight regain after GLP-1 receptor agonist discontinuation is well-documented across the class. STEP-4 (semaglutide) and SURMOUNT-4 (tirzepatide) data both showed substantial regain of lost weight within 12 months of stopping therapy. Orforglipron would be expected to behave similarly as a mechanism-class effect, not a peculiarity of the drug. ATTAIN-MAINTAIN specifically addresses the maintenance question for patients switching from injectable GLP-1s onto oral orforglipron.
Common Questions
Who Orforglipron Is NOT For
- •Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) — this is a class-wide contraindication for GLP-1 receptor agonists based on rodent thyroid C-cell tumor findings, and orforglipron's label is expected to carry the same warning.
- •Pregnancy — GLP-1 receptor agonists are generally not recommended during pregnancy due to limited human data and theoretical concerns around maternal weight loss and fetal growth; orforglipron is expected to carry similar cautions.
- •History of pancreatitis — acute pancreatitis is a recognized although uncommon adverse event in the GLP-1 class, and patients with a history should avoid or use with specialist input.
- •Severe gastrointestinal disease, including gastroparesis — GLP-1 agonists slow gastric emptying and can exacerbate gastroparesis or complicate endoscopic procedures.
- •Pediatric use — orforglipron has not been studied in pediatric populations.
- •Known hypersensitivity to orforglipron or its excipients.
Drug & Supplement Interactions
Orforglipron's small-molecule structure means its interaction profile is different from peptide GLP-1 agonists in important ways, but several class-level concerns still apply. Gastric emptying is delayed by GLP-1 receptor activation, which can alter the absorption of concomitant oral medications — particularly those with narrow therapeutic windows or rapid-onset requirements. Patients taking oral medications requiring rapid absorption (such as certain hypnotics, analgesics, or emergency medications) should be aware that onset timing may shift. Concurrent use with other glucose-lowering agents, particularly sulfonylureas and insulin, increases hypoglycemia risk and typically requires dose adjustment of those agents. As a cytochrome-P450-metabolized small molecule, orforglipron may have CYP-level interactions that peptide GLP-1 agonists do not, and Lilly's Phase 1 program included dedicated interaction studies. Specific clinically relevant CYP interactions will be defined in the eventual product label; until then, patients on complex medication regimens should disclose any orforglipron exposure (including trial participation) to their prescribing clinicians. Concurrent use with other GLP-1 receptor agonists or dual agonists (tirzepatide, semaglutide, liraglutide) is not clinically indicated and would compound both efficacy and adverse-event profile.
Safety Profile
Common Side Effects
Cautions
- • Not yet FDA-approved — investigational drug
- • Treatment discontinuation due to adverse events: 5.3-10.3% (dose-dependent) vs 2.7% with placebo
- • Safety profile consistent with injectable GLP-1 drug class
- • Long-term safety beyond 72 weeks not yet established
What We Don't Know
Cardiovascular outcomes data is not yet available. Long-term safety beyond the 72-week trial period has not been studied. Effects on bone density, pancreatic health, and thyroid cancer risk (concerns raised with other GLP-1 agonists) are still being evaluated.
Legal Status
United States
As of April 2026, orforglipron is investigational. Eli Lilly has announced plans for global regulatory submissions in 2026 for both obesity and type 2 diabetes, under the brand name Foundayo. It is not FDA-approved, is not available by prescription, and legitimate access is limited to participation in Lilly's clinical trial programs. Product marketed as 'compounded orforglipron' by compounding pharmacies or research-chemical suppliers is not a legitimate access pathway — orforglipron is a small-molecule new chemical entity, not a peptide eligible for traditional 503A compounding, and its identity and purity from non-approved sources cannot be verified.
International
EMA, MHRA, Health Canada, and PMDA (Japan) regulatory pathways are expected to receive submissions in the same 2026 window as the FDA filing, but authorization timing will vary by jurisdiction. As of April 2026, no international regulator has authorized orforglipron for any indication. International access is limited to clinical trial participation.
Sports & Competition
GLP-1 receptor agonists in general are not currently listed on the WADA Prohibited List, and orforglipron is not specifically banned. However, WADA and individual sport bodies monitor weight-loss pharmacology, and the landscape is capable of changing. Athletes subject to anti-doping oversight should verify current status with their governing body before use rather than assume permanence.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Orforglipron is FDA-approved and available by prescription.
Reality
As of April 2026, orforglipron is investigational. Eli Lilly has announced plans for 2026 regulatory submissions under the brand name Foundayo; submission is not approval, and review timelines are measured in months. Legitimate access before approval is limited to clinical trial participation.
Myth
Orforglipron is a peptide like semaglutide.
Reality
Orforglipron is a small-molecule non-peptide GLP-1 receptor agonist. It activates the same receptor as semaglutide and tirzepatide but through a chemically distinct molecule. This is why it has oral bioavailability without SNAC absorption-enhancer technology and does not require fasting before dosing — properties peptide-based oral semaglutide does not share.
Myth
Orforglipron produces weight loss equivalent to injectable semaglutide or tirzepatide.
Reality
Phase 3 results show meaningful but somewhat lower weight loss than top-dose injectable semaglutide and tirzepatide in cross-trial comparison — on the order of 11.2% at 36 mg in ATTAIN-1 over 72 weeks, versus ~13–14% for semaglutide 2.4 mg in STEP-1 and ~20–22% for tirzepatide 15 mg in SURMOUNT-1. The trade-off orforglipron offers is convenience (oral, no injection, no fasting), not higher efficacy.
Myth
You can buy orforglipron from a compounding pharmacy or research-chemical supplier.
Reality
Orforglipron is a small-molecule new chemical entity, not a peptide, and falls outside the scope of 503A compounding. Any product marketed as 'compounded orforglipron' ahead of FDA approval should be treated as unverified at best and misrepresented at worst; identity, purity, and dosing accuracy cannot be assumed.
Myth
Because orforglipron is a pill rather than an injection, it is safer than injectable GLP-1s.
Reality
Route of administration does not determine safety. Orforglipron's adverse-event profile in Phase 3 trials is consistent with the GLP-1 class — GI effects dominate, with treatment discontinuation rates in the 5.3–10.3% range depending on dose. Class-wide warnings (thyroid C-cell tumor concerns, pancreatitis history, gastroparesis exacerbation) are expected to apply. Pill form changes convenience, not pharmacology.
Published Research
6 studiesOrforglipron for obesity in people with type 2 diabetes (ATTAIN-2).
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.
ATTAIN-1: 3,127 patients, 72 weeks, 11.2% weight loss at 36 mg
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1).
Efficacy and safety of oral orforglipron in patients with type 2 diabetes.
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
Orforglipron (LY3502970), a novel oral non-peptide glucagon-like peptide-1 receptor agonist: Phase 1a study.
Quick Facts
- Class
- Incretin Mimetic
- Tier
- A
- Evidence
- Moderate
- Safety
- Limited Data
- Updated
- Apr 2026
- Citations
- 6PubMed
Also known as
Tags
Peptide Families
Related Goals
Conditions Discussed
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.